Feature Reports

This page features: Cited Research Articles Ranitidine, most commonly known by its brand name Zantac, is sold by the drug company Sanofi. Zantac has been prescribed by health care professionals since the FDA approved it in 1983 for the treatment of gastroesophageal reflux disease, heartburn, and ulcers. It is also available in generic form. By 1988, …

Zantac, once the world’s best-selling drug, has been treating reflux but causing cancer Read More »

This page features: Cited Research Articles On April 1, 2020, The FDA ordered all prescription and over-the-counter ranitidine drugs, most commonly known as Zantac, pulled from the market immediately.  Patients are strongly advised by the FDA to cease using any Zantac currently in their possession and to consult with their physician on finding another treatment option. Once a …

Zantac Recall Linked to Cancer Risk Read More »

This page features: Cited Research Articles The FDA announced on September 13, 2019, that low levels of a probable human carcinogen called N-nitrosodimethlylamine (NDMA), are found in Zantac (ranitidine). Then, on January 8, 2020, the FDA alerted patients and health care professionals of two voluntary recalls of the drug known by the name of Zantac (ranitidine) …

Zantac found to be potential cancer risk by FDA due to NDMA Carcinogen Read More »